Key facts
- It has raised $124.8M across 6 recorded rounds; the latest was Early Stage VC ($11.0M) in Aug 2025.
- Notable investors include National Institutes of Health, TEDCO, Takeda Ventures, Abell Foundation, State of Maryland — 21 tracked in total.
- Gliknik has filed 16 Form Ds with the SEC since 2009, most recently Aug 2025 ($11.0M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Gliknik
Funding rounds
6 roundsAbout Gliknik
Operator of a biopharmaceutical company intended to treat cancer and autoimmune diseases. The company offers a drug module for the immune system to fight disease and ease human suffering by creating new therapies for people living with cancer and immune disorders, enabling patients to get therapies that make a difference in their lives by reducing suffering.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2007
- Website
- gliknik.com/
- Ownership
- Privately Held (backing)
Gliknik doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gliknik shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gliknik in its N-PORT filings yet. We sweep new filings monthly.